Analysis of disease progression in patients with transthyretin cardiac amyloidosis

Gelijkaardige items

• Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis
  door: Gillmore, Julian D, et al.
  Gepubliceerd in: (2015)
• DISCOVERY: a study examining the prevalence of transthyretin mutations in subjects suspected of having cardiac amyloidosis
  door: Akinboboye, Olakunle, et al.
  Gepubliceerd in: (2015)
• Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
  door: Law, Steven, et al.
  Gepubliceerd in: (2020)
• The Truth Is Unfolding About Transthyretin Cardiac Amyloidosis
  door: Grodin, Justin L., et al.
  Gepubliceerd in: (2019)
• Transthyretin Cardiac Amyloidosis in Black Americans
  door: Shah, Keyur B., et al.
  Gepubliceerd in: (2016)